Docetaxel is currently indicated for androgen-independent, metastatic prostate cancer; there is also evidence demonstrating the role of CYP1B1 in modulating the activity of the drug. We present the case of a man with residual disease after radical prostatectomy treated successfully with docetaxel chemotherapy. After only two cycles of therapy, a complete remission was obtained and then consolidated with additional cycles of docetaxel and radiotherapy. Prospective genetic analysis had shown that the patient had a favourable CYP1B1 genotype. He has been disease free since August 2006. Prospective trials investigating this strategy are warranted.
Durable Complete Response to Frontline Docetaxel in an Advanced Prostate Cancer Patient with Favourable CYP1B1 Isoforms: Suggestion for Changing Paradigms? / BRANDI G; DE ROSA F; DANESI R; MONTINI GC; BIASCO G. - In: EUROPEAN UROLOGY. - ISSN 0302-2838. - ELETTRONICO. - 54:4(2008), pp. 938-941. [10.1016/j.eururo.2008.07.029]
Durable Complete Response to Frontline Docetaxel in an Advanced Prostate Cancer Patient with Favourable CYP1B1 Isoforms: Suggestion for Changing Paradigms?
BRANDI, GIOVANNI;BIASCO, GUIDO
2008
Abstract
Docetaxel is currently indicated for androgen-independent, metastatic prostate cancer; there is also evidence demonstrating the role of CYP1B1 in modulating the activity of the drug. We present the case of a man with residual disease after radical prostatectomy treated successfully with docetaxel chemotherapy. After only two cycles of therapy, a complete remission was obtained and then consolidated with additional cycles of docetaxel and radiotherapy. Prospective genetic analysis had shown that the patient had a favourable CYP1B1 genotype. He has been disease free since August 2006. Prospective trials investigating this strategy are warranted.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
